Verrica Inks Israel Distribution Deal for YCANTH, Adding Up to $8.2M in Milestones
VRCA sits 77% above its 52-week low of $3.28 on light trading volume (0.1× avg).
Summary
Verrica signed an exclusive distribution agreement with Medomie Pharma to commercialize YCANTH for molluscum contagiosum in Israel. Verrica will supply the product and receive 60% of the net selling price, plus up to $8.2 million in regulatory and commercial milestones. This expands YCANTH's global footprint beyond the U.S. and Japan, adding a new revenue stream for a company with a going concern warning and limited cash runway. The deal provides non-dilutive capital and validates demand for the product in new markets. No specific timeline for Israeli regulatory approval was disclosed.
At the time of this announcement, VRCA was trading at $5.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $94.3M. The 52-week trading range was $3.28 to $9.82. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.